Page last updated: 2024-09-02

landiolol and Metastase

landiolol has been researched along with Metastase in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aragaki, M; Hamasaki, T; Hida, Y; Horie, N; Nojiri, T; Onda, K; Sato, N; Yamamoto, H	1

Trials

1 trial(s) available for landiolol and Metastase

Article	Year
Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients. Trials, 2019, Dec-11, Volume: 20, Issue:1 Topics: Adrenergic beta-1 Receptor Antagonists; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Humans; Japan; Lung Neoplasms; Morpholines; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pneumonectomy; Progression-Free Survival; Randomized Controlled Trials as Topic; Time Factors; Urea	2019

Article

Year

Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients.

Trials, 2019, Dec-11, Volume: 20, Issue:1

Topics: Adrenergic beta-1 Receptor Antagonists; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Humans; Japan; Lung Neoplasms; Morpholines; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pneumonectomy; Progression-Free Survival; Randomized Controlled Trials as Topic; Time Factors; Urea

2019